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Synopsis: The significance of nodal metastasis in breast cancer is under discussion. We investigated the impact of
variables of tumor chronology and tumor biology on the presence of lymph node metastases.
Purpose: Lymph node involvement is the main prognostic factor in breast cancer. However, it is under discussion
whether nodal metastasis in breast cancer only reflects the chronological age of the tumor or whether it is also a
marker of tumor biology. The goal of our study was to investigate the impact of variables of tumor chronology and
biology on the presence of lymph node metastases.
Methods: We performed a retrospective analysis of data from 3002 patients with an early invasive breast
carcinoma. All patients underwent primary surgery at the University Hospitals Leuven between 2001 and 2009. First,
the impact of tumor size on the presence of lymph node metastasis was evaluated as the chronological age of a
tumor is supposed to be reflected in its size. Next, the impact of tumor grade, lymphovascular invasion and the
hormone receptor status, which are all variables of tumor biology, was studied. Logistic regression analyses were
performed and the area under the ROC curve (AUC) was calculated as a measure of discrimination between logistic
regression models.
Results: Using pathological tumor size the AUC of prediction was 0.67. Based on variables of tumor biology, axillary
lymph node positivity could be predicted with an AUC of 0.68. Combining variables of tumor chronology and
biology an AUC of 0.74 for the prediction of axillary lymph node (ALN) positivity was calculated.
Conclusions: According to our data variables of tumor chronology and tumor biology have a similar impact on the
presence of lymph node metastasis.
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Lymph node involvement is the main prognostic factor
in breast cancer and a crucial component of the staging
system. However, the significance of nodal metastasis in
breast cancer is under discussion. It has been considered
a reflection of the chronological age of the tumor since
the time of Halsted (Mittra 1993; Tubiana-Hulin et al.
1995; Paterson et al. 1982; Mittra & MacRae 1991). This
view was based on the concept that breast cancer always* Correspondence: ann.smeets@uzleuven.be
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in any medium, provided the original work is pspreads to the regional lymph nodes first and to distant
sites afterwards. The improved prognosis of patients
with node-negative tumors was attributed to timely
resection of the tumor. An alternative reason for the dif-
ference in prognosis between node-negative and node-
positive patients could be that the nodal status in breast
cancer is also a marker of tumor biology (Jatoi et al.
1999). Understanding the significance of lymph node in-
volvement could provide important insights into cancer
growth and allow more rational decision-making in clin-
ical practice.
The primary goal of this study was to evaluate the im-
pact of variables of tumor chronology and those of
tumor biology on lymph node positivity. The chrono-
logical age of the tumor is supposed to be reflectedan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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strong relationship between the pathological size of
a tumor (pT) and axillary lymph node metastasis
(Carter et al. 1989).Variables of tumor biology are tumor
grade, lymphovascular invasion (LVI), the hormone re-
ceptor status (ER/PR/HER-2) and multifocality. The cor-
relation of these variables with the presence of lymph
node involvement has been investigated extensively
(Patani et al. 2007). In our study, multifocality was not
studied as we included only unifocal tumors.
Secondly, we assessed whether accurate prediction of
lymph node involvement is possible preoperatively, as in
the preoperative setting only clinical tumor size (cT),




Data were obtained by retrospective review of the Multi-
disciplinary Breast Center database from the University
Hospitals Leuven (Leuven, Belgium). Patients with a pri-
mary operable breast cancer between 1 January 2001
and 31 December 2009 were included in the study. The
local surgical treatment consisted of wide excision of the
tumor followed by radiotherapy, or mastectomy with or
without radiotherapy. All patients underwent axillary sta-
ging by sentinel lymph node (SLN) biopsy and/or axillary
lymph node dissection. We excluded patients (i) treated
for a local recurrence, (ii) with only a carcinoma in situ,
(iii) who received neo-adjuvant therapy, (iv) with primary
metastatic disease and (v) with a multifocal tumor.
Tumor size and nodal status were defined according
to TNM standards (AJCC) (Greene 2002). cT is the
largest measured tumor size using clinical examination
and imaging (mammography, ultrasound or MRI). pT is
the largest diameter measured on final pathology of
representative slides of the surgical resection specimen.
Pathological node positivity included micro- and macro-
metastases.
Sentinel lymph node localization
The SLN procedure was performed by injection of a radio-
active (99mTc-labelled nanocolloid) tracer at the level
of the tumor and Patent Blue V dye® (Guerbet, France)
retroareolar. The SLNs were removed surgically with the
assistance of a hand-held gamma-ray detection probe.
Examination of the lymph nodes
SLNs were routinely examined by serial sectioning. Every
300 μm 2 sections were stained, 1 with routine haema-
toxylin and eosin (H&E) and 1 stained immunohistoche-
mically using monoclonal antibodies against cytokeratin.
Lymph nodes in an axillary lymph node dissection were
examined by H&E staining using 3 sections per node.According to published guidelines, lymph nodes from
lobular breast cancers, classified as lymph node negative
on H&E, were additionally stained with epithelial
markers (Greene 2002).
Statistical methodology
Clinical characteristics were summarized with absolute
number (n), mean and standard deviation for continuous
variables and by observed counts for categorical vari-
ables. The correlation between the selected variables of
tumor chronology and biology and lymph node involve-
ment was determined by using logistic regression ana-
lysis. Only patients with all available data were included.
The area under the ROC curves (AUC) were calculated
to discriminate between both regression models. The
difference between the two models was assessed using
the methods described by DeLong, DeLong and Clarke-
Pearson (DeLong et al. 1988). The impact of variables of
tumor biology on the presence of lymph node metastasis
was measured by the combination of tumor grade, LVI,
ER, PR and HER-2.
The AUC of a model including all variables known in
the preoperative setting, was calculated and compared
with the AUC of the model including all variables
known in the postoperative setting.
All analyses were performed using SAS software, ver-
sion 9.2 (SAS Institute, Cary, NC).
Results
Out of a total database of 10390 patients, 4124 patients
were found to meet the inclusion criteria. Patients with
missing tumor data were excluded, resulting in 3002 tu-
mors for analysis. The mean age was 57.8 years. The
mean pathological tumor size was 22.2 mm. A sentinel
lymph node biopsy was performed in 1476 patients,
followed by an axillary lymph node dissection only when
the sentinel lymph node was positive. The remaining
1526 patients underwent an axillary lymph node dissec-
tion. Fifty-nine percent of patients were node-negative
and 41% were node-positive. Thirty percent of patients
were pN1, 7% pN2 and 4% pN3
Univariate analysis
Table 1 shows the univariate analysis between clinico-
pathological characteristics and the presence of lymph
node metastasis. Positive nodal status was significantly
correlated with cT, pT, tumor grade, the presence of LVI
and HER-2. No significant correlation was found be-
tween lymph node involvement and ER and PR.
Logistic regression analysis
Impact of variables of tumor chronology on pN
As mentioned before, the chronological age of the tumor
is supposed to be reflected through its size. In the
Table 1 Univariate analysis between clinicopathologial characteristics and the presence of lymph node metastasis
Patient characteristic Negative Positive Total P-value
N = 1778 N = 1224 N = 3002
Age (mean ± SD) 57.8 ± 12.42 57.5 ± 12.48 57.7 ± 12.45
Tumor size (mean ± SD) 22.2 ± 13.83 35.6 ± 24.33 27.7 ± 19.94
cT (n,%) 1 1015 (57.09) 430 (35.13) 1445 (48.13) <.001
2 683 (38.41) 636 (51.96) 1319 (43.94)
3 71 (3.99) 127 (10.38) 198 (6.60)
4 9 (0.51) 31 (2.53) 40 (1.33)
pN (n,%) 0 1778 (100) 0 (0) 1778 (59.23) <.001
1 0 (0) 907 (74.10) 907 (30.21)
2 0 (0) 211 (17.24) 211 (7.03)
3 0 (0) 106 (8.66) 106 (3.53)
Tumor grade (n,%) 1 317 (17.83) 130 (10.62) 447 (14.89) <.001
2 761 (42.80) 519 (42.40) 1280 (42.64)
3 700 (39.37) 575 (46.98) 1275 (42.47)
LVI (n,%) No 1606 (90.33) 709 (57.92) 2315 (77.12) <.001
Yes 172 (9.67) 515 (42.08) 687 (22.88)
ER (n,%) Negative 275 (15.52) 186 (15.20) 462 (15.39) 0.807
Positive 1502 (84.48) 1038 (84.80) 2540 (84.61)
PR (n,%) Negative 465 (26.15) 322 (26.31) 787 (26.22) 0.925
Positive 1313 (73.85) 902 (73.69) 2215 (73.78)
HER-2 (n,%) Negative 1608 (90.44) 1064 (86.93) 2672 (89.01) 0.003
Positive 170 (9.56) 160 (13.07) 330 (10.99)
Table 2 Logistic regression analyses for the prediction of the presence of lymph node metastasis by variables of tumor
chronology and biology
Fitted model (N = 3002) Predictor Effect Odds ratio (95% CI) P-value AUC (95% CI)
cT cT 1 vs 4 0.123 (0.058; 0.2610) <.0001 0.6231 (0.6048; 0.6414)
2 vs 4 0.270 (0.128; 0.572)
3 vs 4 0.519 (0.234; 1.152)
pT pT 1 vs 4 0.129 (0.050; 0.332) <.0001 0.6700 (0.6522; 0.6877)
2 vs 4 40.352 (0.137; 0.906)
3 vs 4 1.338 (0.501; 3.575)
LVI LVI Yes vs No 6.782 (5.587; 8.234) <.0001 0.6620 (0.6466; 0.6775)
Grade Grade 1 vs 3 0.499 (0.396; 0.630) <.0001 0.5531 (0.5341; 0.5721)
2 vs 3 0.830 (0.710; 0.971)
ER ER Neg vs Pos 0.975 (0.797; 1.194) 0.8076 0.5016 (0.4885; 0.5148)
PR PR Neg vs Pos 1.008 (0.854; 1.189) 0.9248 0.5008 (0.4848; 0.5168)
HER–2 HER-2 Neg vs Pos 0.703 (0.559; 0.884) 0.0026 0.5176 (0.5059; 0.5292)
grade, ER, PR, HER–2 0.5649 (0.5448; 0.5850)
cT, grade, ER, PR, HER–2 0.6406 (0.6206; 0.6606)
LVI, grade, ER, PR, HER–2 0.6852 (0.6657; 0.7047)
pT, LVI, grade, ER, PR, HER–2 0.7462 (0.7279; 0.7645)
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erative setting the pT is used. Logistic regression analysis
showed that in a model only including chronological
tumor characteristics, the presence of lymph node me-
tastases could be predicted with an AUC of 0.62 when
cT was used and with an AUC of 0.67 when pT was
used (Table 2).Impact of variables of tumor biology on pN
Next, logistic regression analyses of models including
variables of tumor biology were performed. A model in-
cluding LVI could predict lymph node positivity with an
AUC of 0.66. Models including tumor grade, ER, PR or
HER-2 could only predict lymph node involvement with
AUCs of 0.55, 0.50, 0.50 and 0.51 respectively. Discrim-
ination accuracy for lymph node involvement of tumor
grade combined with LVI, ER, PR and HER-2 was 0.68
(Table 2).Figure 1 ROC curves for the prediction of the presence of lymph nod
biology (LVI, grade, ER, PR & HER-2) and the combination of both.Impact of variables of tumor chronology plus tumor
biology on pN
When combining pT and variables of tumor biology axil-
lary nodal positivity could be predicted with an AUC of
0.74. In the preoperative setting, the presence of lymph
node metastasis could be predicted with an AUC of 0.64
(Table 2).Comparison of ROC curves
Comparison of ROC curves showed that (i) the impact
of variables of tumor chronology and tumor biology on
lymph node positivity was similar, (ii) the addition of
variables of tumor biology to variables of tumor chron-
ology significantly improved the prediction of lymph
node metastasis (p<0.0001) and (iii) prediction of the
presence of lymph node metastasis in the postoperative
setting was significantly better than in the preoperative
setting (p<0.0001) (Figure 1 and Figure 2).e metastasis by variables of tumor chronology (pT), tumor
Figure 2 ROC curves for the prediction of the presence of lymph node metastasis by variables known in the preoperative (cT, grade,
ER, PR & HER-2) and the postoperative (pT, LVI, grade, ER, PR & HER-2) setting.
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The exclusion of patients with missing data could intro-
duce serious bias into the results, unless the missing
data is completely at random (MCAR scenario). The bias
by excluding patients without available data was prob-
ably small in this study because the odds ratios from
univariate analysis were similar when all patients were
included as when only patients with all available data
were included (data not shown).Discussion
The results of this study show that lymph node involve-
ment in breast cancer reflects both tumor chronology
and biology. Using pathological tumor size, lymph node
involvement can be predicted with an AUC of 0.67. The
combination of variables of tumor biology can predict
lymph node involvement with an AUC of 0.68. Thus,
based on our data, tumor chronology and biology seem
to have a similar impact on the lymph node status.
When using the combination of pathological tumor size,
LVI, tumor grade, ER, PR and HER-2 the lymph node
status can be predicted with an AUC of 0.74.The chronological age of a tumor can be considered as
a product of the tumor size and host resistance to the
tumor divided by its biological aggressiveness (Mittra
1993). In this study, we used only tumor size to measure
the chronological age of the tumor as it is evident that
tumor size increases over time and is easily measurable.
On the other hand, host resistance to the tumor and the
biological aggressiveness of the disease are less accur-
ately defined. The strong direct relationship between the
size of a tumor and axillary lymph node metastasis is
well established (Fisher et al. 1969). An analysis of
data on 24740 cases of breast cancer recorded in the
SEER program of the National Cancer Institute has
demonstrated that this relationship is strictly linear
(Carter et al. 1989).
Besides tumor size, variables of tumor biology have
been shown to correlate with axillary lymph node in-
volvement (Patani et al. 2007; Yoshihara et al. 2012). We
used LVI, tumor grade, ER, PR and HER-2 to evaluate
the impact of tumor biology on the presence of lymph
node metastasis. ER, PR and HER-2 receptor status have
not been found to be consistently related to lymph node
status. However, we included them in the analysis as
Smeets et al. SpringerPlus 2013, 2:480 Page 6 of 7
http://www.springerplus.com/content/2/1/480they are important variables of tumor biology. Multifo-
cality was not evaluated as only unifocal tumors were in-
cluded in our study. The addition of tumor grade, ER,
PR and HER-2 to LVI had only a limited impact on the
prediction of the lymph node status (AUC 0.66 => 0.68).
It could be questioned whether LVI reflects tumor
biology or tumor chronology. Rakha et al. recently dem-
onstrated that it is an independent prognostic factor.
Univariate analysis showed a significant correlation be-
tween LVI and tumor size and between LVI and the
nodal status but in multivariate analysis LVI remained
an independent predictor of survival. Multivariate ana-
lysis including the interaction between LVI and lymph
node status and tumor size, did not result in significant
Pinteraction values, indicating that the effects of LVI on pa-
tient outcomes were not affected significantly by the
lymph node status or tumor size (Rakha et al. 2012).
Moreover, LVI can not simply be considered as the first
step in the process of lymph node involvement as in our
series 57% of the tumors from patients with lymph node
positive breast cancer did not show LVI. These data con-
firm that LVI is a parameter of tumor biology.
To evaluate whether the lymph node status can be
accurately predicted in the preoperative setting, we de-
termined the impact of cT, tumor grade, ER, PR and
HER-2 on the lymph node status. Based on these vari-
ables, axillary lymph node positivity could be predicted
with an AUC of 0.64. There is no perfect correlation be-
tween the tumor grade on core biopsy and on the resec-
tion specimen. Hence, it might be that the actual AUC is
even lower than 0.64. These data demonstrate that an
accurate prediction of the lymph node status is not pos-
sible in the preoperative setting.
Mittra et al. did not find a significant correlation be-
tween most biological prognostic factors and lymph
node involvement and thus concluded that the axillary
node status is merely a reflection of the chronological
age of breast cancer. However, their data showed a sig-
nificant correlation between tumor grade and the lymph
node status. So, their conclusion does not seem to be
fully supported by their data. Moreover, they did not in-
clude LVI as a biological prognostic factor while, as
mentioned above, LVI has been shown to be an inde-
pendent prognostic factor (Rakha et al. 2012).
Our findings are in line with these of Jatoi et al. (Jatoi
et al. 1999). They showed that patients with four or
more involved nodes at initial diagnosis have a signifi-
cantly worse outcome after relapse than patients with
node-negative breast cancer, and thus that nodal metas-
tasis is not only a marker of diagnosis at a later point in
the evolution of the disease but also a marker of an ag-
gressive phenotype.
Understanding the significance of lymph node involve-
ment provides insight into cancer growth and controlthat can be applied in clinical practice. For example,
based on our data, tumor size should not determine the
selection of patients for a sentinel lymph node proced-
ure as (1) variables of tumor chronology and tumor biol-
ogy have a similar impact on the lymph node status and
(2) prediction of the lymph node status based on clinical
tumor size is not accurate (AUC 0.62). Moreover, the
findings of this study allow for more individualized clin-
ical decision making, for example to estimate the risk of
lymph node involvement in patients with an unexpected
finding of an invasive tumor on final pathology.
Several nomograms have been developed to predict
the likelihood of sentinel lymph node metastases, based
on clinical variables. A nomogram developed at the
Memorial Sloan-Kettering Cancer Center (New York,
NY) includes nine variables: age, tumor size, tumor type,
LVI, multifocality, nuclear grade, tumor location, and ER
and PR status (Bevilacqua et al. 2007). It can predict the
presence of lymph node metastases in the sentinel
lymph node with an AUC of 0.75. This is a reasonable
prediction rate.
By combining variables of tumor chronology and biol-
ogy, we were able to predict ALN positivity with an
AUC of 0.74. Many clinically useful predictive models
have an AUC in this range. (van la Parra et al. 2013)
Nevertheless, an AUC of 0.74 indicates that, besides
the chronological age of the tumor and specific bio-
logical features, other variables have an impact on the
lymph node status. One such variable is the location of
the tumor in the breast. Patients with lateral and
retroareolar tumors have a higher probability of positive
lymph nodes compared to patients with medial tumors
(Yoshihara et al. 2013). Moreover, the lymph node status
might be a marker of the host response to the tumor.
Hence, it could be hypothesized that a weakened host
response results in early metastasis to the axillary lymph
nodes (Jatoi et al. 1999).
Conclusion
According to our data, variables of tumor chronology
and tumor biology seem to have a similar impact on the
presence of lymph node metastasis. Based on patho-
logical tumor size, the presence of LVI, tumor grade, ER,
PR and HER-2, the presence of axillary lymph node me-
tastasis can be predicted with an AUC of 0.74.
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